WO2014001191A1 - Magnesium alloy, method for the production thereof and use thereof - Google Patents

Magnesium alloy, method for the production thereof and use thereof Download PDF

Info

Publication number
WO2014001191A1
WO2014001191A1 PCT/EP2013/062876 EP2013062876W WO2014001191A1 WO 2014001191 A1 WO2014001191 A1 WO 2014001191A1 EP 2013062876 W EP2013062876 W EP 2013062876W WO 2014001191 A1 WO2014001191 A1 WO 2014001191A1
Authority
WO
WIPO (PCT)
Prior art keywords
weight
alloy
magnesium
precipitations
content
Prior art date
Application number
PCT/EP2013/062876
Other languages
French (fr)
Inventor
Heinz Mueller
Peter Uggowitzer
Joerg Loeffler
Original Assignee
Biotronik Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to RU2015102168A priority Critical patent/RU2647951C2/en
Application filed by Biotronik Ag filed Critical Biotronik Ag
Priority to KR1020147033397A priority patent/KR102246885B1/en
Priority to JP2015518992A priority patent/JP6786214B2/en
Priority to EP13729770.1A priority patent/EP2864514B1/en
Priority to CN201380022714.6A priority patent/CN104284993B/en
Priority to CA2869458A priority patent/CA2869458C/en
Priority to AU2013283577A priority patent/AU2013283577A1/en
Priority to US14/395,954 priority patent/US10895000B2/en
Priority to ES13729770T priority patent/ES2796371T3/en
Priority to SG11201406024QA priority patent/SG11201406024QA/en
Priority to BR112014032618-5A priority patent/BR112014032618B1/en
Publication of WO2014001191A1 publication Critical patent/WO2014001191A1/en
Priority to HK15101370.1A priority patent/HK1200881A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C22METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22CALLOYS
    • C22C23/00Alloys based on magnesium
    • C22C23/04Alloys based on magnesium with zinc or cadmium as the next major constituent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02Inorganic materials
    • A61L27/04Metals or alloys
    • A61L27/047Other specific metals or alloys not covered by A61L27/042 - A61L27/045 or A61L27/06
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/58Materials at least partially resorbable by the body
    • CCHEMISTRY; METALLURGY
    • C22METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22CALLOYS
    • C22C23/00Alloys based on magnesium
    • C22C23/02Alloys based on magnesium with aluminium as the next major constituent
    • CCHEMISTRY; METALLURGY
    • C22METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22FCHANGING THE PHYSICAL STRUCTURE OF NON-FERROUS METALS AND NON-FERROUS ALLOYS
    • C22F1/00Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working
    • CCHEMISTRY; METALLURGY
    • C22METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22FCHANGING THE PHYSICAL STRUCTURE OF NON-FERROUS METALS AND NON-FERROUS ALLOYS
    • C22F1/00Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working
    • C22F1/06Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working of magnesium or alloys based thereon

Definitions

  • This patent application relates to a magnesium alloy and to a method for the production thereof and to the use thereof.
  • magnesium alloys are decisively defined by the type and quantity of the alloying elements and impurities as well as the production conditions.
  • the effects of the alloying elements and impurities on the properties of the magnesium alloys have been known for a long time to a person skilled in the art and illustrate the complex nature of determining the properties of binary or ternary magnesium alloys for the use thereof as implant materials.
  • the alloying element used most frequently for magnesium is aluminum, resulting in increased tensile strength due to solid solution and precipitation hardening and fine grain formation, but also in microporosity. Moreover, in the melt aluminum shifts the iron precipitation boundary toward drastically lower iron contents at which the iron particles precipitate or form intermetallic particles together with other elements.
  • Undesirable accompanying elements in magnesium alloys include iron, nickel, cobalt and copper, which cause a considerable increase in the corrosion tendency due to the electropositive nature thereof.
  • the electrochemical potential of this phase is very high and can thus act as a cathode controlling the corrosion of the alloy matrix.
  • zirconium Alloying additions made of zirconium increase the tensile strength without lowering the expansion and lead to grain refining, but also to a strong impairment of dynamic restrystallization, which is manifested in an increase of the recrystallization temperature and therefore requires high energy expenditure. Moreover, zirconium cannot be added to melts containing aluminum and silicon because the grain refining effect is lost.
  • Rare earths such as Lu, Er, Ho, Th, Sc and In all exhibit a similar chemical behavior and form eutectic systems with partial solubility on the magnesium-rich side of the binary phase diagrams such that precipitation hardening is possible.
  • intermetallic phase Mg 17 Al 12 forming on the grain boundaries is brittle and limits the ductility.
  • this intermetallic phase is more noble and able to form local elements, whereby the corrosion behavior worsens.
  • the properties of the magnesium alloys also decisively depend on the metallurgical production conditions.
  • Conventional casting methods automatically introduce impurities when adding, by alloying, the alloying elements.
  • the prior art (US 5,055,254 A) therefore defines tolerance limits for impurities in magnesium casting alloys, which, for example for a magnesium-aluminum-zinc alloy containing approximately 8 to 9.5% by weight Al and 0.45 to 0.9% by weight Zn, mentions tolerance limits of 0.0015 to 0.0024% by weight Fe, 0.0010% Ni, 0.0010 to 0.0024% by weight Cu and no less than 0.15 to 0.5% by weight Mn. Tolerance limits for impurities in magnesium and the alloys thereof as well
  • Biodegradable implants require a load-bearing function and consequently strength, together with sufficient expandability, during the physiologically necessary support periods thereof.
  • the known magnesium materials cannot come even close to the properties achieved by permanent implants such as titanium, CoCr alloys and titanium alloys.
  • the ultimate tensile strength R m for permanent implants is approximately 500 MPa to >1000 MPa, while that of magnesium materials is ⁇ 275 MPa so far, and in most cases ⁇ 250 MPa.
  • magnesium materials such as the alloys containing 3 to 10% by weight Al and less than 1% by weight Zn and Mn (AZ group), for example, additionally exhibit a clearly pronounced mechanical asymmetry, which is manifested in the difference in the mechanical properties, especially the proof stress R p with tension load and compression load.
  • Such asymmetries are created, for example, during forming processes such as extrusion, rolling and drawing, which are used to produce suitable semi-finished products.
  • a difference between the proof stress R p during tension and the proof stress R p during compression that is too large may result in inhomogeneous deformation of a component, such as a cardiovascular stent, which later undergoes multiaxial deformation, and may cause cracking and fracture.
  • magnesium alloys can generally also form textures during forming processes such as extrusion, rolling and drawing used to produce suitable semifinished products by orienting the grains during the forming process. Specifically, this means that the semifinished product has different properties in different directions in space. For example, high deformability or elongation at fracture occurs in one direction in space after forming, and reduced deformability or elongation at fracture occurs in another direction in space.
  • the formation of such textures should likewise be avoided, because a stent is subjected to high plastic deformation, and reduced elongation at fracture increases the risk of failure of the implant.
  • One method for substantially avoiding such textures during forming is to adjust as fine a grain as possible prior to forming.
  • the ability of these materials to deform at room temperature is low, which is characterized by slip in the base plane. If the material additionally has a coarse microstructure, which is to say a coarse grain, so-called twinning is forcibly produced upon further deformation, at which shear strain occurs, which transforms a crystal region into a position that is mirror symmetrical to the starting position.
  • the resulting twin grain boundaries constitute weak points in the material, where incipient cracking starts, especially with plastic deformation, which ultimately leads to the destruction of the component.
  • Implant materials should therefore have as fine a grain as possible so as to prevent such undesirable shear strain.
  • All available technical magnesium materials for implants are subject to high corrosion in physiological media. Attempts have been made in the prior art to curb the corrosion tendency by providing the implants with a corrosion-inhibiting coating, for example made of polymeric materials (EP 2 085 100 A2, EP 2 384 725 Al), an aqueous or alcoholic conversion solution (DE 10 2006 060 501 Al) or an oxide (DE 10 2010 027 532 Al, EP 0 295 397 Al).
  • a corrosion-inhibiting coating for example made of polymeric materials (EP 2 085 100 A2, EP 2 384 725 Al), an aqueous or alcoholic conversion solution (DE 10 2006 060 501 Al) or an oxide (DE 10 2010 027 532 Al, EP 0 295 397 Al).
  • Degradable magnesium alloys are especially suitable for implementing implants which have been employed in a wide variety of forms in modern medical technology. Implants are used, for example, to support vessels, hollow organs and vein systems (endovascular implants, such as stents), for fastening and temporarily fixing tissue implants and tissue transplantations, but also for orthopedic purposes, such as nails, plates or screws. A particularly frequently used form of an implant is the stent.
  • stents have the purpose of assuming a supporting function in hollow organs of a patient.
  • stents featuring conventional designs have a filigree supporting structure comprising metal struts, which is initially present in compressed form for introduction into the body and is expanded at the site of the application.
  • One of the main application areas of such stents is to permanently or temporarily widen and hold open vascular constrictions, particularly constrictions (stenosis) of coronary blood vessels.
  • aneurysm stents are known, which are used primarily to seal the aneurysm.
  • the support function is additionally provided.
  • the implant notably the stent, has a base body made of an implant material.
  • An implant material is a non-living material, which is employed for applications in medicine and interacts with biological systems.
  • biocompatibility shall be understood to mean the ability of a material to induce an appropriate tissue reaction in a specific application. This includes an adaptation of the chemical, physical, biological, and morphological surface properties of an implant to the recipient's tissue with the aim of a clinically desired interaction.
  • the biocompatibility of the implant material is also dependent on the temporal process of the reaction of the biosystem in which it is implanted.
  • the implant materials can be divided into bioactive, bioinert and degradable or resorbable materials.
  • Implant materials comprise polymers, metallic materials, and ceramic materials (as coatings, for example).
  • Biocompatible metals and metal alloys for permanent implants comprise, for example, stainless steels (such as 316L), cobalt-based alloys (such as CoCrMo cast alloys, CoCrMo forge alloys, CoCrWNi forge alloys and CoCrNiMo forge alloys), technical pure titanium and titanium alloys (such as cp titanium, TiA16V4 or TiA16Nb7) and gold alloys.
  • stainless steels such as 316L
  • cobalt-based alloys such as CoCrMo cast alloys, CoCrMo forge alloys, CoCrWNi forge alloys and CoCrNiMo forge alloys
  • technical pure titanium and titanium alloys such as cp titanium, TiA16V4 or TiA16Nb7
  • gold alloys such as gold alloys.
  • the objects of the invention are that of providing a biodegradable magnesium alloy, a method for the production thereof and a use for implants, which allow the magnesium matrix of the implant to remain in an electrochemically stable state over the required support period with fine grain and high corrosion resistance without protective layers, while also improving the mechanical properties, such as increasing the tensile strength and proof stress, as well as reducing the mechanical asymmetry.
  • the solution according to the invention is based on the realization that the corrosion resistance and deformability of the magnesium matrix of the implant must be assured over the support period such that the implant is able to absorb multiaxial permanent load without fracture or cracking, and to also utilize the magnesium matrix as a means for the decomposition triggered by the physiological liquids.
  • the magnesium alloy comprising:
  • the magnesium alloy according to the invention has extraordinarily high corrosion resistance, which is achieved by drastically reducing the content of impurities and the combinations thereof in the magnesium matrix, and by also adding precipitation and solid solution hardenable elements, which must be present in completely solid solution.
  • the micro structure that is obtained has no electrochemical potential differences between the individual matrix phases after the forming and heat treatment processes, and therefore these differences cannot expedite the corrosion in physiological media.
  • an alloy matrix which has a content of Zn of preferably 1.5 to 5.5%> by weight, and more particularly 3.5 to 5.5%> by weight, and a content of Al of preferably at least 0.5 to 2.0% by weight, and more particularly 1.0 to 2.0% by weight, can form, or depending on the treatment forms, a mixed crystal from Zn and Al, which are present completely in solution form, without precipitations, the mixed crystal having a higher standard potential than unalloyed high-grade magnesium and therefore the alloy being more noble.
  • Another surprising result is that, at a content of Zn of preferably 3.0 to 7.0% by weight, and more particularly 4.0 to 6.0% by weight, and a content of Al of preferably 0.5 to 3.5%) by weight, and more particularly 1.5 to 2.5% by weight, an alloy is obtained which contains precipitations in the form of Mg3Zn3Al 2 und MgZn and has an extremely small grain size, wherein the precipitations having a size of less than 1 ⁇ , and preferably 0.2 ⁇ , are located both on the grain boundaries and in the grain interior.
  • the alloying elements may be present in the alloy in amounts even slightly above the solubility limit. Controlled by the cooling conditions during the production of the alloy, the alloying elements are initially present in solution. During forming of the alloy at temperatures below the solubility limit, for example at 250°C, fine particles are precipitated during forming which prevent grain growth and then contribute to an increase in tensile strength, both due to particle hardening and grain refining hardening. Through subsequent aging of the formed semi- finished product at temperatures below the temperature at which the alloying elements go completely into solution, for example 200°C, it is also possible to precipitate fine particles, which continue to remain in the matrix during the later thermomechanical treatment steps so as to prevent grain growth and increase the strength.
  • the alloy according to the invention has particularly high corrosion resistance. This is achieved by drastically reducing the contents of certain elements, and combinations of certain elements, in the alloy matrix whereby a microstructure is obtained in which, contrary to all known technically available magnesium materials, electrochemical differences in potential no longer occur between the individual matrix phases, and these therefore no longer play a role in terms of an expedited corrosion of the material in physiological media.
  • the alloy according to the invention contains Al, it is particularly important to limit not only elements such as Ni, Co or Cu, which in general have a considerable adverse effect on the corrosion resistance of magnesium alloys, but notably the elements Fe, Mn and Si.
  • a corrosion-stable alloy matrix can be achieved when complying with the following tolerance limits of individual impurities in % by weight: Fe, Si, Mn, Co, Ni, Cu each with ⁇ 0.0005; Zr, Y each with ⁇ 0.0003; Sc or
  • rare earths having the ordinal numbers 21, 57 to 71 and 89 to 103 in total
  • the corrosion-staple alloy matrix contains impurities in a total amount of no more than 0.0053 Gew.%, which can be achieved when complying with the following tolerance limits of individual impurities in % by weight:
  • the corrosion-staple alloy matrix contains impurities in a total amount of no more than 0.0022 Gew.%, which can be achieved when complying with the following tolerance limits of individual impurities in % by weigh n:
  • rare earths having the ordinal numbers 21, 57 to 71 and 89 to 103 in total
  • the formation of precipitations or particles which have a positive potential difference as compared to the matrix is entirely suppressed, or drastically reduced, if the sum of individual impurities consisting of Fe, Si, Mn, Co, Ni and Cu is no more than 0.0030%) by weight, preferably no more than 0.0021% by weight, and particularly preferably no more than 0.0009% by weight.
  • the particular advantage of the alloy according to the invention is that it no longer has any relevant contents of Fe, Si or Mn and only Zn and Al remain in the material, which increase the corrosion resistance of magnesium and increase the strength, however no elements are present which could form effective cathodes for corrosion processes. Such low concentrations moreover no longer allow a formation of intermetallic phases, which have a more positive electrochemical potential as compared to the matrix. Because the Zr content is considerably below that of the prior art, no Zr-rich phases can form, which are always more noble than the magnesium matrix and thus act as cathodic sites which promote corrosion.
  • the tendency toward stress and vibration corrosion is advantageously decreased, counteracting a rapid weakening of the mechanical strength.
  • Such low concentrations thus also ensure that the magnesium matrix no longer contains any, or contains only small amounts of, precipitations or particle phases, which have a more positive electrochemical potential as compared to the matrix.
  • these precipitations or particles of the elements contained in the alloy according to the present application allow the tensile strength of the magnesium matrix to be increased and the electrochemical potential of the matrix to be raised, whereby a corrosion-decreasing effect is created, notably with respect to physiological media.
  • the precipitations preferably have a size of no more than 1 ⁇ , and preferably of no more than 0.2 ⁇ , and are located on the grain boundaries and in the grain interior, whereby the movement of grain boundaries during thermal treatment as well as dislocations during deformation are impaired and the strength of the magnesium alloy is increased.
  • the magnesium alloy according to the present patent application achieves a tensile strength of >275 MPa, and preferably >300 MPa, a yield point of >200 MPa, and preferably >225 MPa, and a yield ratio of ⁇ 0.8, and preferably ⁇ 075, wherein the difference between the tensile strength and yield point is >50 MPa, and preferably >100 MPa, and the mechanical asymmetry is ⁇ 1.25.
  • the magnesium alloy So as to minimize the mechanical asymmetry, it is particularly important for the magnesium alloy to have a particularly fine micro structure having a grain size of no more than 7.5 ⁇ , preferably ⁇ 5 ⁇ , and particularly preferably ⁇ 2.5 ⁇ .
  • the objects are moreover achieved by a method for producing a magnesium alloy having improved mechanical and electrochemical properties.
  • the method comprises the following steps:
  • step b) generating a billet of the alloy by synthesis of the magnesium according to step a) with high-purity Zn and Al in a composition of 1.5 to 7.0% by weight Zn, 0.5 to 3.5% by weight Al, the remainder being magnesium containing impurities, which promote electrochemical potential differences and/or the formation of precipitations and/or intermetallic phases, in a total amount of no more than 0.0063% by weight of Fe, Si, Mn, Co, Ni, Cu, Zr, Y and Sc or rare earths having the ordinal numbers 21, 57 to 71 and 89 to 103, Be, Cd, In, Sn and/or Pb as well as P, wherein the alloy content of Zn in % by weight is greater than or equal to the alloy content of Al in % by weight;
  • step d) optionally heat treating the formed alloy in the temperature range between 200°C and 350°C with a holding period of 5 minute to 6 hours.
  • step c) is performed alloy in the temperature range between 270°C and 350°C.
  • the forming temperature for example 270°C to 330°C, is adhered to so as to ensure that the solubility limit for the individual elements is not exceeded. This prevents particles from forming in the matrix, which can have a corrosion-accelerating effect.
  • a content of Zn of preferably 3.0 to 7.0% by weight, and more particularly 4.0 to 6.0%) by weight, and a content of Al of preferably 0.5 to 3.5% by weight, and more particularly 1.5 to 2.5% by weight means that the alloying element may be present in amounts slightly higher than the solubility limit.
  • the shaping process after homogenizing annealing, at temperatures of 200°C to 350°C below the solubility limit according to step d) prevents precipitations in the Mgi 7 Ali 2 phase and causes only fine particles to be precipitated in the matrix in the form of Mg 3 Zn 3 Al 2 und MgZn, which impair grain growth and contribute to an increase in the tensile strength of the alloy due to particle hardening and grain refining hardening.
  • temperatures at which the alloying elements are caused to go completely into solution typically, these are temperatures of 20°C to 325°C
  • Vacuum distillation is preferably used to produce a starting material for the alloy according to the present patent application having the required threshold values.
  • the quantities of the alloying elements Zn and Al as well as the sum of impurities can be selectively adjusted and in % by weight are: for the individual impurities:
  • precipitations having a grain size of 1 ⁇ , and preferably 0.2 ⁇ form on the grain boundaries and in the interior of the grains, whereby the tensile strength of the alloy reaches values which at >275 MPa, and preferably >300 MPa, are considerably higher than the prior art.
  • a third concept of the patent application relates to the use of the magnesium alloy produced according to the method, which has the aforedescribed advantageous composition and structure, in medical technology, notably for the production of implants, for example endovascular implants such as stents, for fastening and temporarily fixing tissue implants and tissue transplantations, orthopedic and dental implants, and neuro implants.
  • implants for example endovascular implants such as stents, for fastening and temporarily fixing tissue implants and tissue transplantations, orthopedic and dental implants, and neuro implants.
  • cardiovascular system i.e. heart and blood vessel system
  • active and non-active implants used to support vessels, and vein systems including coronary, cerebral and peripheral vascular implants like stents, valves, closure devices, occluders, clips, coils, staples, implantable regional drug delivery devices,
  • implantable electrostimulators like pacemakers and defibrillators
  • implantable monitoring devices implantable electrodes
  • stent as mechanical fix or temporary scaffold to support hollow organs (or bodies?) including bones, intervertebral disks Osteosynthesis in the sense of this application means
  • a magnesium alloy is to be generated which is composed of 5% by weight Zn and 2% by weight Al, the remainder being Mg, in which the alloying elements are present completely in solution form, and which contains the following individual impurities in % by weight:
  • Fe ⁇ 0.0005; Si: ⁇ 0.0005; Mn: ⁇ 0.0005; Co: ⁇ 0.0002; Ni: ⁇ 0.0002; Cu ⁇ 0.0002, wherein the sum of impurities consisting of Fe, Si, Mn, Co, Ni and Cu should be no more than 0.0021% by weight, the content of Zr ⁇ 0.0003% by weight, the content of Y ⁇ 0.0001% by weight, the content of rare earths having the ordinal numbers 21, 39, 57 to 71 and 89 to 103 in total should be less than 0.001% by weight, and the contents of Be and Cd should be no more than 0.0001% by weight, respectively, and P ⁇ 0.0001.
  • This alloy produced using magnesium vacuum distillation, is subjected to homogenizing annealing at a temperature of 300°C for a duration of 48 hours, and subsequently to a forming process at a temperature of 275°C to 300°C, which is above the solubility limit.
  • a precision tube for a cardiovascular stent is produced by multiple extrusion and annealing processes above the solubility limit at 275°C so as to prevent the precipitation of Mg 3 Zn 3 Al 2 particles.
  • the grain size that was achieved was ⁇ 10 ⁇ , and the magnesium alloy reached a tensile strength of more than 300 MPa and proof stress of ⁇ 230 MPa.
  • the yield ratio was 0.72 and the mechanical asymmetry was 1.15.
  • a magnesium alloy is to be produced, which is composed of 5.5% by weight Zn and 3% by weight Al, the remainder being magnesium, in which some of the alloying elements are present as particles in the form of MgZnAl having a size of ⁇ 0.5 ⁇ , and which contains the following individual impurities in % by weight:
  • Fe ⁇ 0.0005; Si: ⁇ 0.0005; Mn: ⁇ 0.0005; Co: ⁇ 0.0002; Ni: ⁇ 0.0002; Cu ⁇ 0.0002, wherein the sum of impurities consisting of Fe, Si, Mn, Co, Ni and Cu should be no more than 0.0021% by weight, the content of Zr ⁇ 0.0003% by weight, the content of Y ⁇ 0.0001% by weight, the content of rare earths having the ordinal numbers 21, 39, 57 to 71 and 89 to 103 in total should be less than 0.001% by weight, and the contents of Be and Cd should be no more than 0.0001% by weight, respectively, and P ⁇ 0.0001.
  • the magnesium alloy is produced in a manner which corresponds to that of Example 1. So as to precipitate some of the MgZnAl particles, an extrusion process is carried out above the solubility limit at temperatures of ⁇ 275°C.
  • the precision tubes for a cardiovascular stent were produced by multiple extrusion and annealing processes, in part below the solubility limit.
  • the solubility limit was 330°C.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Mechanical Engineering (AREA)
  • Metallurgy (AREA)
  • Organic Chemistry (AREA)
  • Thermal Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dermatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Inorganic Chemistry (AREA)
  • Materials For Medical Uses (AREA)
  • Powder Metallurgy (AREA)
  • Dental Preparations (AREA)
  • Manufacture And Refinement Of Metals (AREA)

Abstract

The patent application relates to a magnesium alloy and to a method for the production thereof and to the use thereof, the magnesium alloy comprising: 1.5 to 7.0% by weight Zn, 0.5 to 3.5% by weight Al, the remainder being magnesium which contains impurities, which promote electrochemical potential differences and/or the formation of precipitations and/or intermetallic phases, in a total amount of no more than 0.0063% by weight of Fe, Si, Mn, Co, Ni, Cu, Zr, Y, Sc or rare earths having the ordinal numbers 21, 57 to 71 and 89 to 103, Be, Cd, In, Sn and/or Pb as well as P.

Description

MAGNESIUM ALLOY, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF
This patent application relates to a magnesium alloy and to a method for the production thereof and to the use thereof.
It is known that the properties of magnesium alloys are decisively defined by the type and quantity of the alloying elements and impurities as well as the production conditions. The effects of the alloying elements and impurities on the properties of the magnesium alloys have been known for a long time to a person skilled in the art and illustrate the complex nature of determining the properties of binary or ternary magnesium alloys for the use thereof as implant materials.
The alloying element used most frequently for magnesium is aluminum, resulting in increased tensile strength due to solid solution and precipitation hardening and fine grain formation, but also in microporosity. Moreover, in the melt aluminum shifts the iron precipitation boundary toward drastically lower iron contents at which the iron particles precipitate or form intermetallic particles together with other elements.
Undesirable accompanying elements in magnesium alloys include iron, nickel, cobalt and copper, which cause a considerable increase in the corrosion tendency due to the electropositive nature thereof.
Manganese can be found in all magnesium casting alloys and binds iron in the form of AlMnFe precipitations, whereby the formation of local elements is reduced. On the other hand, manganese is not able to bind all the iron, and therefore a remainder of iron and a remainder of manganese are always left in the melt. Silicon lowers the castability and viscosity, and as the content of Si rises, a worsened corrosion behavior is to be expected. Iron, manganese and silicon have a very high tendency to form an intermetallic phase.
The electrochemical potential of this phase is very high and can thus act as a cathode controlling the corrosion of the alloy matrix.
As a result of solid solution hardening, zinc improves the mechanical properties and results in grain refining, however it also leads to microporosity with a tendency toward hot cracking starting at a content of 1.5 to 2% by weight in binary Mg-Zn and ternary Mg-Al-Zn alloys.
Alloying additions made of zirconium increase the tensile strength without lowering the expansion and lead to grain refining, but also to a strong impairment of dynamic restrystallization, which is manifested in an increase of the recrystallization temperature and therefore requires high energy expenditure. Moreover, zirconium cannot be added to melts containing aluminum and silicon because the grain refining effect is lost.
Rare earths such as Lu, Er, Ho, Th, Sc and In all exhibit a similar chemical behavior and form eutectic systems with partial solubility on the magnesium-rich side of the binary phase diagrams such that precipitation hardening is possible.
The addition of further alloying elements, in conjunction with the impurities, is known to cause the formation of different intermetallic phases in binary magnesium alloys. For example, the intermetallic phase Mg17Al12 forming on the grain boundaries is brittle and limits the ductility. As compared to the magnesium matrix, this intermetallic phase is more noble and able to form local elements, whereby the corrosion behavior worsens.
In addition to these influencing factors, the properties of the magnesium alloys also decisively depend on the metallurgical production conditions. Conventional casting methods automatically introduce impurities when adding, by alloying, the alloying elements. The prior art (US 5,055,254 A) therefore defines tolerance limits for impurities in magnesium casting alloys, which, for example for a magnesium-aluminum-zinc alloy containing approximately 8 to 9.5% by weight Al and 0.45 to 0.9% by weight Zn, mentions tolerance limits of 0.0015 to 0.0024% by weight Fe, 0.0010% Ni, 0.0010 to 0.0024% by weight Cu and no less than 0.15 to 0.5% by weight Mn. Tolerance limits for impurities in magnesium and the alloys thereof as well
as the production conditions are mentioned in many known documents and
listed as follows in % by weight:
Figure imgf000004_0001
It has been found that these tolerance definitions are not sufficient to reliably exclude the formation of corrosion-promoting intermetallic phases, which in terms of electrochemistry have a more noble potential than the magnesium matrix.
Biodegradable implants (orthopedics, traumatology, cardiovascular implants) require a load-bearing function and consequently strength, together with sufficient expandability, during the physiologically necessary support periods thereof. However, especially in this respect, the known magnesium materials cannot come even close to the properties achieved by permanent implants such as titanium, CoCr alloys and titanium alloys. The ultimate tensile strength Rm for permanent implants is approximately 500 MPa to >1000 MPa, while that of magnesium materials is <275 MPa so far, and in most cases <250 MPa.
Another drawback of many technical magnesium materials is that the difference thereof between ultimate tensile strength Rm and proof stress Rp is only small. In the case of implants that allow plastic deformation, such as cardiovascular stents, this means that no further resistance exists against deformation after initial deformation of the material, and the regions that have already been deformed are deformed further without any load increase, whereby overstretching of parts of the component may be caused and fracture may occur.
Many magnesium materials, such as the alloys containing 3 to 10% by weight Al and less than 1% by weight Zn and Mn (AZ group), for example, additionally exhibit a clearly pronounced mechanical asymmetry, which is manifested in the difference in the mechanical properties, especially the proof stress Rp with tension load and compression load. Such asymmetries are created, for example, during forming processes such as extrusion, rolling and drawing, which are used to produce suitable semi-finished products. A difference between the proof stress Rp during tension and the proof stress Rp during compression that is too large may result in inhomogeneous deformation of a component, such as a cardiovascular stent, which later undergoes multiaxial deformation, and may cause cracking and fracture.
Because of the low number of crystallographic slip systems, magnesium alloys can generally also form textures during forming processes such as extrusion, rolling and drawing used to produce suitable semifinished products by orienting the grains during the forming process. Specifically, this means that the semifinished product has different properties in different directions in space. For example, high deformability or elongation at fracture occurs in one direction in space after forming, and reduced deformability or elongation at fracture occurs in another direction in space. The formation of such textures should likewise be avoided, because a stent is subjected to high plastic deformation, and reduced elongation at fracture increases the risk of failure of the implant. One method for substantially avoiding such textures during forming is to adjust as fine a grain as possible prior to forming. Because of the hexagonal lattice structure of magnesium materials, the ability of these materials to deform at room temperature is low, which is characterized by slip in the base plane. If the material additionally has a coarse microstructure, which is to say a coarse grain, so-called twinning is forcibly produced upon further deformation, at which shear strain occurs, which transforms a crystal region into a position that is mirror symmetrical to the starting position. The resulting twin grain boundaries constitute weak points in the material, where incipient cracking starts, especially with plastic deformation, which ultimately leads to the destruction of the component.
If the grain of the implant materials is sufficiently fine, the risk of such implant failure is drastically reduced. Implant materials should therefore have as fine a grain as possible so as to prevent such undesirable shear strain.
All available technical magnesium materials for implants are subject to high corrosion in physiological media. Attempts have been made in the prior art to curb the corrosion tendency by providing the implants with a corrosion-inhibiting coating, for example made of polymeric materials (EP 2 085 100 A2, EP 2 384 725 Al), an aqueous or alcoholic conversion solution (DE 10 2006 060 501 Al) or an oxide (DE 10 2010 027 532 Al, EP 0 295 397 Al).
The use of polymeric passivation layers is highly contested, because virtually all appropriate polymers also cause strong inflammations in the tissue at times. Thin structures without such protective measures do not reach the required support periods. The corrosion on thin-walled traumato logical implants is often times accompanied by an excessively fast loss of tensile strength, which poses an additional burden by forming excessive amounts of hydrogen per unit of time. The consequences are undesirable gas inclusions in the bones and tissue.
In the case of traumato logical implants having larger cross-sections, there is a need to be able to deliberately control the hydrogen problem and the corrosion rate of the implant by way of the structure thereof.
Specifically with biodegradable implants, there is a desire for maximum biocompatibility of the elements, because all the chemical elements that are contained are absorbed by the body after decomposition. In any case, highly toxic elements such as Be, Cd, Pb, Cr and the like should be avoided.
Degradable magnesium alloys are especially suitable for implementing implants which have been employed in a wide variety of forms in modern medical technology. Implants are used, for example, to support vessels, hollow organs and vein systems (endovascular implants, such as stents), for fastening and temporarily fixing tissue implants and tissue transplantations, but also for orthopedic purposes, such as nails, plates or screws. A particularly frequently used form of an implant is the stent.
The implantation of stents has become established as one of the most effective therapeutic measures for the treatment of vascular diseases. Stents have the purpose of assuming a supporting function in hollow organs of a patient. For this purpose, stents featuring conventional designs have a filigree supporting structure comprising metal struts, which is initially present in compressed form for introduction into the body and is expanded at the site of the application. One of the main application areas of such stents is to permanently or temporarily widen and hold open vascular constrictions, particularly constrictions (stenosis) of coronary blood vessels. In addition, aneurysm stents are known, which are used primarily to seal the aneurysm. The support function is additionally provided.
The implant, notably the stent, has a base body made of an implant material. An implant material is a non-living material, which is employed for applications in medicine and interacts with biological systems. A basic prerequisite for the use of a material as an implant material, which is in contact with the body environment when used as intended, is the body friendliness thereof (biocompatibility). For the purpose of the present application, biocompatibility shall be understood to mean the ability of a material to induce an appropriate tissue reaction in a specific application. This includes an adaptation of the chemical, physical, biological, and morphological surface properties of an implant to the recipient's tissue with the aim of a clinically desired interaction. The biocompatibility of the implant material is also dependent on the temporal process of the reaction of the biosystem in which it is implanted. For example, irritations and inflammations occur in a relatively short time, which can lead to tissue changes. Depending on the properties of the implant material, biological systems thus react in different ways. According to the reaction of the biosystem, the implant materials can be divided into bioactive, bioinert and degradable or resorbable materials. Implant materials comprise polymers, metallic materials, and ceramic materials (as coatings, for example). Biocompatible metals and metal alloys for permanent implants comprise, for example, stainless steels (such as 316L), cobalt-based alloys (such as CoCrMo cast alloys, CoCrMo forge alloys, CoCrWNi forge alloys and CoCrNiMo forge alloys), technical pure titanium and titanium alloys (such as cp titanium, TiA16V4 or TiA16Nb7) and gold alloys. In the field of biocorrodible stents, the use of magnesium or technical pure iron as well as biocorrodible base alloys of the elements magnesium, iron, zinc, molybdenum, and tungsten are proposed.
The use of biocorrodible magnesium alloys for temporary implants having filigree structures is made difficult in particular in that the degradation of the implant progresses very quickly in vivo. So as to reduce the corrosion rate, this being the degradation speed, different approaches are being discussed. For one, it is attempted to slow the degradation on the part of the implant material by developing appropriate alloys. In addition, coatings are to bring about a temporary inhibition of the degradation. While the existing approaches are promising, none of them has so far led to a commercially available product. Regardless of the efforts made so far, there is rather a continuing need for solutions that make it possible to at least temporarily reduce the corrosion of magnesium alloys in vivo, while optimizing the mechanical properties thereof at the same time.
In light of this prior art, the objects of the invention are that of providing a biodegradable magnesium alloy, a method for the production thereof and a use for implants, which allow the magnesium matrix of the implant to remain in an electrochemically stable state over the required support period with fine grain and high corrosion resistance without protective layers, while also improving the mechanical properties, such as increasing the tensile strength and proof stress, as well as reducing the mechanical asymmetry.
These objects are achieved by a magnesium alloy having the characteristics of claim 1, a method having the characteristics of claim 10, and the use according to the characteristics of claims 19 to 22. The characteristics listed in the dependent claims allow advantageous refinements of the magnesium alloy according to the invention, of the method for the production thereof according to the invention, and the use.
The solution according to the invention is based on the realization that the corrosion resistance and deformability of the magnesium matrix of the implant must be assured over the support period such that the implant is able to absorb multiaxial permanent load without fracture or cracking, and to also utilize the magnesium matrix as a means for the decomposition triggered by the physiological liquids.
This is achieved by the magnesium alloy comprising:
1.5 to 7.0% by weight Zn, 0.5 to 3.5% by weight Al, the remainder being magnesium which contains impurities, which promote electrochemical potential differences and/or the formation of precipitations and/or intermetallic phases, in a total amount of no more than 0.0063%) by weight of Fe, Si, Mn, Co, Ni, Cu, Zr, Y, Sc or rare earths having the ordinal numbers 21, 57 to 71 and 89 to 103, Be, Cd, In, Sn and/or Pb as well as P, wherein the alloy content of Zn in % by weight is greater than or equal to the alloy content of Al in % by weight.
The magnesium alloy according to the invention has extraordinarily high corrosion resistance, which is achieved by drastically reducing the content of impurities and the combinations thereof in the magnesium matrix, and by also adding precipitation and solid solution hardenable elements, which must be present in completely solid solution. The micro structure that is obtained has no electrochemical potential differences between the individual matrix phases after the forming and heat treatment processes, and therefore these differences cannot expedite the corrosion in physiological media.
The applicant surprisingly found that an alloy matrix, which has a content of Zn of preferably 1.5 to 5.5%> by weight, and more particularly 3.5 to 5.5%> by weight, and a content of Al of preferably at least 0.5 to 2.0% by weight, and more particularly 1.0 to 2.0% by weight, can form, or depending on the treatment forms, a mixed crystal from Zn and Al, which are present completely in solution form, without precipitations, the mixed crystal having a higher standard potential than unalloyed high-grade magnesium and therefore the alloy being more noble.
Care should be taken that the alloy contents of Zn and Al are exactly adjusted such that the content in solid solution is as high as possible, and therefore maximum corrosion protection is achieved, without exceeding the solubility limit. Typical forming temperatures for this alloy range between 270 and 330°C under these conditions. This prevents particles from forming in the alloy matrix, which could take on the functions of cathodes during the corrosion process and thus promote corrosion.
Another surprising result is that, at a content of Zn of preferably 3.0 to 7.0% by weight, and more particularly 4.0 to 6.0% by weight, and a content of Al of preferably 0.5 to 3.5%) by weight, and more particularly 1.5 to 2.5% by weight, an alloy is obtained which contains precipitations in the form of Mg3Zn3Al2 und MgZn and has an extremely small grain size, wherein the precipitations having a size of less than 1 μιη, and preferably 0.2 μιη, are located both on the grain boundaries and in the grain interior.
In this case, the alloying elements may be present in the alloy in amounts even slightly above the solubility limit. Controlled by the cooling conditions during the production of the alloy, the alloying elements are initially present in solution. During forming of the alloy at temperatures below the solubility limit, for example at 250°C, fine particles are precipitated during forming which prevent grain growth and then contribute to an increase in tensile strength, both due to particle hardening and grain refining hardening. Through subsequent aging of the formed semi- finished product at temperatures below the temperature at which the alloying elements go completely into solution, for example 200°C, it is also possible to precipitate fine particles, which continue to remain in the matrix during the later thermomechanical treatment steps so as to prevent grain growth and increase the strength.
The alloy according to the invention has particularly high corrosion resistance. This is achieved by drastically reducing the contents of certain elements, and combinations of certain elements, in the alloy matrix whereby a microstructure is obtained in which, contrary to all known technically available magnesium materials, electrochemical differences in potential no longer occur between the individual matrix phases, and these therefore no longer play a role in terms of an expedited corrosion of the material in physiological media.
The previously known tolerance limits for impurities do not take into account that wrought magnesium alloys often times are subjected to a thermo mechanical treatment, and more particularly to an extended annealing process, which creates near-equilibrium structures. The metallic elements bond by way of diffusion and form what are known as intermetallic phases, which have a different electrochemical potential, notably a considerably higher potential, than the magnesium matrix, and therefore these intermetallic phases act as cathodes and can trigger galvanic corrosion processes.
Because the alloy according to the invention contains Al, it is particularly important to limit not only elements such as Ni, Co or Cu, which in general have a considerable adverse effect on the corrosion resistance of magnesium alloys, but notably the elements Fe, Mn and Si.
When producing such an alloy according to the prior art, both a remainder of Fe and a remainder of Mn are left in the melt. In addition, such melts are not purified with respect to Si. However, Fe, Mn and Si have a very high tendency to form a ternary intermetallic Fe-Mn-Si phase, which has a very positive potential and thus constitutes a very effective cathode for the corrosion of the material. Moreover, Al additionally shifts the boundary in the melt at which iron begins to precipitate as iron particles or intermetallic particles with other elements toward drastically lower iron contents.
The applicant has found that a corrosion-stable alloy matrix can be achieved when complying with the following tolerance limits of individual impurities in % by weight: Fe, Si, Mn, Co, Ni, Cu each with <0.0005; Zr, Y each with <0.0003; Sc or
rare earths having the ordinal numbers 21, 57 to 71 and 89 to 103 in total
<0.001; Be, Cd, In, Sn and/or Pb each with <0.0003; and P <0.0002.
Preferably the corrosion-staple alloy matrix contains impurities in a total amount of no more than 0.0053 Gew.%, which can be achieved when complying with the following tolerance limits of individual impurities in % by weight:
Fe, Si, Mn each with <0.0005; Co, Ni, Cu each with <0.0002; Zr, Y each
with <0.0003; Sc or rare earths having the ordinal numbers 21, 57 to 71 and
89 to 103 in total <0.001 ; Be, Cd, In, Sn and/or Pb each with <0.0003; and P
<0.0001.
In particular preferred the corrosion-staple alloy matrix contains impurities in a total amount of no more than 0.0022 Gew.%, which can be achieved when complying with the following tolerance limits of individual impurities in % by weigh n:
Fe, Si, Mn each with <0.0002; Co, Ni, Cu, Zr, Y each with <0.0001 ; Sc or
rare earths having the ordinal numbers 21, 57 to 71 and 89 to 103 in total
<0.0005; Be, Cd, In, Sn and/or Pb each with <0.0001, and P <0.0001.
The formation of precipitations or particles which have a positive potential difference as compared to the matrix is entirely suppressed, or drastically reduced, if the sum of individual impurities consisting of Fe, Si, Mn, Co, Ni and Cu is no more than 0.0030%) by weight, preferably no more than 0.0021% by weight, and particularly preferably no more than 0.0009% by weight.
The particular advantage of the alloy according to the invention is that it no longer has any relevant contents of Fe, Si or Mn and only Zn and Al remain in the material, which increase the corrosion resistance of magnesium and increase the strength, however no elements are present which could form effective cathodes for corrosion processes. Such low concentrations moreover no longer allow a formation of intermetallic phases, which have a more positive electrochemical potential as compared to the matrix. Because the Zr content is considerably below that of the prior art, no Zr-rich phases can form, which are always more noble than the magnesium matrix and thus act as cathodic sites which promote corrosion.
By limiting the yttrium content, the tendency toward stress and vibration corrosion is advantageously decreased, counteracting a rapid weakening of the mechanical strength.
Because the chemical elements of a magnesium alloy from biodegradable implants are absorbed by the human body, additionally the amounts of highly toxic elements such as Be, CD, In, Sn and/or Pb as well as rare earths (elements having the ordinal numbers 21, 57 to 71 and 89 to 103) must be limited in the alloy so as to achieve high biocompatibility, while also suppressing the formation of intermetallic phases between these elements and magnesium, aluminum and zinc.
Such low concentrations thus also ensure that the magnesium matrix no longer contains any, or contains only small amounts of, precipitations or particle phases, which have a more positive electrochemical potential as compared to the matrix.
In the connection with solid solution hardening by Zn and Al, these precipitations or particles of the elements contained in the alloy according to the present application allow the tensile strength of the magnesium matrix to be increased and the electrochemical potential of the matrix to be raised, whereby a corrosion-decreasing effect is created, notably with respect to physiological media. The precipitations preferably have a size of no more than 1 μιη, and preferably of no more than 0.2 μιη, and are located on the grain boundaries and in the grain interior, whereby the movement of grain boundaries during thermal treatment as well as dislocations during deformation are impaired and the strength of the magnesium alloy is increased.
The magnesium alloy according to the present patent application achieves a tensile strength of >275 MPa, and preferably >300 MPa, a yield point of >200 MPa, and preferably >225 MPa, and a yield ratio of <0.8, and preferably <075, wherein the difference between the tensile strength and yield point is >50 MPa, and preferably >100 MPa, and the mechanical asymmetry is <1.25.
These significantly improved mechanical properties of the novel magnesium alloy assure that the implants, for example cardiovascular stents, are able to withstand the multiaxial permanent load in the implanted state over the entire support period, despite onsetting degradation of the magnesium matrix due to corrosion.
So as to minimize the mechanical asymmetry, it is particularly important for the magnesium alloy to have a particularly fine micro structure having a grain size of no more than 7.5 μιη, preferably < 5 μιη, and particularly preferably < 2.5 μιη.
The objects are moreover achieved by a method for producing a magnesium alloy having improved mechanical and electrochemical properties. The method comprises the following steps:
a) generating high-purity magnesium by way of vacuum distillation;
b) generating a billet of the alloy by synthesis of the magnesium according to step a) with high-purity Zn and Al in a composition of 1.5 to 7.0% by weight Zn, 0.5 to 3.5% by weight Al, the remainder being magnesium containing impurities, which promote electrochemical potential differences and/or the formation of precipitations and/or intermetallic phases, in a total amount of no more than 0.0063% by weight of Fe, Si, Mn, Co, Ni, Cu, Zr, Y and Sc or rare earths having the ordinal numbers 21, 57 to 71 and 89 to 103, Be, Cd, In, Sn and/or Pb as well as P, wherein the alloy content of Zn in % by weight is greater than or equal to the alloy content of Al in % by weight;
c) homogenizing the alloy by annealing at a temperature between 250°C and 350°C with a holding period of 1 to 60 hours and cooling by exposure to air and in a water bath;
c) at least single forming of the homogenized alloy in the temperature range between 250°C and 350°C; and
d) optionally heat treating the formed alloy in the temperature range between 200°C and 350°C with a holding period of 5 minute to 6 hours. In a preferred embodiment, step c) is performed alloy in the temperature range between 270°C and 350°C.
A content of Zn of preferably 1.5 to 5.5% by weight, and more particularly 3.5 to 5.5% by weight, and a content of Al of preferably at least 0.2 to 2.0% by weight, and more particularly 1.0 to 2.0% by weight, assures that the microstructure of the alloy is a mixed crystal made of Zn and Al, which are present completely in solution form, without precipitations, the mixed crystal having a higher standard potential than the high-grade magnesium. During subsequent forming, care must be taken that the forming temperature, for example 270°C to 330°C, is adhered to so as to ensure that the solubility limit for the individual elements is not exceeded. This prevents particles from forming in the matrix, which can have a corrosion-accelerating effect.
In contrast, a content of Zn of preferably 3.0 to 7.0% by weight, and more particularly 4.0 to 6.0%) by weight, and a content of Al of preferably 0.5 to 3.5% by weight, and more particularly 1.5 to 2.5% by weight means that the alloying element may be present in amounts slightly higher than the solubility limit. The shaping process, after homogenizing annealing, at temperatures of 200°C to 350°C below the solubility limit according to step d) prevents precipitations in the Mgi7Ali2 phase and causes only fine particles to be precipitated in the matrix in the form of Mg3Zn3Al2 und MgZn, which impair grain growth and contribute to an increase in the tensile strength of the alloy due to particle hardening and grain refining hardening. Through subsequent aging of the formed semifinished product below temperatures at which the alloying elements are caused to go completely into solution (typically, these are temperatures of 20°C to 325°C), it is possible to precipitate particles, which continue to remain in the matrix during the later thermomechanical treatment, prevent grain growth processes and further increase the strength.
Vacuum distillation is preferably used to produce a starting material for the alloy according to the present patent application having the required threshold values.
The quantities of the alloying elements Zn and Al as well as the sum of impurities can be selectively adjusted and in % by weight are: for the individual impurities:
Fe, Si, Mn, Co, Ni, Cu each with <0.0005;
Zr, Y each with <0.0003;
Sc or rare earths having the ordinal numbers 21, 57 to 71 and 89 to 103
in total <0.001;
Be, Cd, In, Sn and/or Pb each with <0.0003; and
P <0.0002. aa) for the individual impurities in a preferred total amount of impurities of no more than 0.0053% by weight,:
Fe, Si, Mn each with <0.0005;
Co, Ni, Cu each with <0.0002;
Zr, Y each with <0.0003;
Sc or rare earths having the ordinal numbers 21, 57 to 71 and 89 to
103 in total <0.001;
Be, Cd, In, Sn and/or Pb each with <0.0003; and
P O.0001. ab) for the individual impurities in a particularly preferred total amount of impurities of no more than 0.0022% by weight:
Fe, Si, Mn each with <0.0002;
Co, Ni, Cu, Zr, Y each with <0.0001 ;
Sc or rare earths having the ordinal numbers 21 , 57 to 71 and 89 to
103 in total O.0005;
Be, Cd, In, Sn and/or Pb each with O.0001 ; and
P O.0001.
for the combination of individual impurities in total:
Fe, Si, Mn, Co, Ni and Cu no more than 0.0040, preferably no more than 0.0020, and particularly preferably no more than 0.0010. It is particularly advantageous that the method described here only requires a small number of forming steps. Extrusion, equal channel angular extrusion and/or multiple forging can thus preferably be employed, which assure that a substantially homogeneous fine grain of <15 μιη is achieved.
Because of the artificial aging, precipitations having a grain size of 1 μιη, and preferably 0.2 μιη, form on the grain boundaries and in the interior of the grains, whereby the tensile strength of the alloy reaches values which at >275 MPa, and preferably >300 MPa, are considerably higher than the prior art.
A third concept of the patent application relates to the use of the magnesium alloy produced according to the method, which has the aforedescribed advantageous composition and structure, in medical technology, notably for the production of implants, for example endovascular implants such as stents, for fastening and temporarily fixing tissue implants and tissue transplantations, orthopedic and dental implants, and neuro implants.
All implants in the sense of this patent application are in the Cardiovascular field, osteosynthesis field or other areas.
Cardiovascular field in the sense of this application means
the field of diagnostic, prevention and treatment of all diseases of the cardiovascular system, i.e. heart and blood vessel system,
by mean of active and non-active implants used to support vessels, and vein systems including coronary, cerebral and peripheral vascular implants like stents, valves, closure devices, occluders, clips, coils, staples, implantable regional drug delivery devices,
implantable electrostimulators (like pacemakers and defibrillators), implantable monitoring devices, implantable electrodes,
system for fastening and temporarily fixing tissue implants and tissue transplantations
field also includes any type of stent as mechanical fix or temporary scaffold to support hollow organs (or bodies?) including bones, intervertebral disks Osteosynthesis in the sense of this application means
the field of treatment of fractured bones for internal fixation and stabilization by mechanical devices such as metal plates, pins, rods, wires, screws, clips, nails, staples excluding stent technology
Examples of areas out of the osteosynthesis field or the cardiovascular field are:
Devices for the treatment of diseases of the sinews, joints, muscles, cartilages, oral (including dental) and maxillo facial implants (excl. osteosynthesis means), esthetic implants,
supporting tools out of the body, (examples?)
tissue engineering,
soft tissue implants,
devices for wound care,
suture material and clamps,
neurosurgery
local drug delivery (excl. cardiovascular, i.e. lever)
renal
Exemplary embodiments Example 1
A magnesium alloy is to be generated which is composed of 5% by weight Zn and 2% by weight Al, the remainder being Mg, in which the alloying elements are present completely in solution form, and which contains the following individual impurities in % by weight:
Fe: <0.0005; Si: <0.0005; Mn: <0.0005; Co: <0.0002; Ni: <0.0002; Cu <0.0002, wherein the sum of impurities consisting of Fe, Si, Mn, Co, Ni and Cu should be no more than 0.0021% by weight, the content of Zr < 0.0003% by weight, the content of Y <0.0001% by weight, the content of rare earths having the ordinal numbers 21, 39, 57 to 71 and 89 to 103 in total should be less than 0.001% by weight, and the contents of Be and Cd should be no more than 0.0001% by weight, respectively, and P <0.0001. This alloy, produced using magnesium vacuum distillation, is subjected to homogenizing annealing at a temperature of 300°C for a duration of 48 hours, and subsequently to a forming process at a temperature of 275°C to 300°C, which is above the solubility limit. A precision tube for a cardiovascular stent is produced by multiple extrusion and annealing processes above the solubility limit at 275°C so as to prevent the precipitation of Mg3Zn3Al2 particles.
The grain size that was achieved was < 10 μιη, and the magnesium alloy reached a tensile strength of more than 300 MPa and proof stress of < 230 MPa. The yield ratio was 0.72 and the mechanical asymmetry was 1.15.
Example 2
A magnesium alloy is to be produced, which is composed of 5.5% by weight Zn and 3% by weight Al, the remainder being magnesium, in which some of the alloying elements are present as particles in the form of MgZnAl having a size of < 0.5 μιη, and which contains the following individual impurities in % by weight:
Fe: <0.0005; Si: <0.0005; Mn: <0.0005; Co: <0.0002; Ni: <0.0002; Cu <0.0002, wherein the sum of impurities consisting of Fe, Si, Mn, Co, Ni and Cu should be no more than 0.0021% by weight, the content of Zr < 0.0003% by weight, the content of Y <0.0001% by weight, the content of rare earths having the ordinal numbers 21, 39, 57 to 71 and 89 to 103 in total should be less than 0.001% by weight, and the contents of Be and Cd should be no more than 0.0001% by weight, respectively, and P <0.0001.
The magnesium alloy is produced in a manner which corresponds to that of Example 1. So as to precipitate some of the MgZnAl particles, an extrusion process is carried out above the solubility limit at temperatures of < 275°C. The precision tubes for a cardiovascular stent were produced by multiple extrusion and annealing processes, in part below the solubility limit. The solubility limit was 330°C. This alloy according to the subject matter of the patent application reached the following properties:
- tensile strength of 310 to 340 MPa;
proof stress of≤ 230 MPa;
a yield ratio of 0.69;
mechanical asymmetry of 1.1 ; and
a grain size of < 5 μιη.

Claims

CLAIMS What is claimed is
1. A magnesium alloy having improved mechanical and electrochemical properties, comprising:
1.5 to 7.0% by weight Zn, 0.5 to 3.5% by weight Al, the remainder being magnesium which contains impurities, which promote electrochemical potential differences and/or the formation of precipitations and/or intermetallic phases, in a total amount of no more than 0.0063%) by weight of Fe, Si, Mn, Co, Ni, Cu, Zr, Y, Sc or rare earths having the ordinal numbers 21, 57 to 71 and 89 to 103, Be, Cd, In, Sn and/or Pb as well as P, wherein the alloy content of Zn in % by weight is greater than or equal to the alloy content of Al in % by weight.
2. The magnesium alloy according to claim 1, characterized in that the content of Zn is preferably 1.5 to 5.5% by weight, and more particularly 3.5 to 5.5% by weight, and the content of Al is preferably at least 0.5 to 2.0% by weight, and more particularly 1.0 to 2.0% by weight, wherein the microstructure of the alloy is a mixed crystal made of Zn and Al, which are present completely in solution form, without precipitations.
3. The magnesium alloy according to claim 1, characterized in that the content of Zn is preferably 3.0 to 7.0% by weight, and more particularly 4.0 to 6.0% by weight, and the content of Al is preferably 0.5 to 3.5% by weight, and more particularly 1.5 to 2.5% by weight, wherein the matrix of the alloy contains only precipitations in the form of Mg3Zn3Al2 and MgZn.
4. The magnesium alloy according to claim 1, characterized in that the individual impurities in the total sum of impurities amount to the following in % by weight: Fe <0.0005; Si <0.0005; Mn <0.0005; Co <0.0005; Ni <0.0005; Cu <0.0005; Zr <0.0003; Y <0.0003; Sc or rare earths having the ordinal numbers 21 , 57 to 71 and 89 to 103 in total <0.001; Be, Cd, In, Sn and/or Pb each with <0.0003; and P <0.0002.
5. The magnesium alloy according to claim 1, characterized in that when the impurity elements Fe, Si, Mn, Co, Ni, and Cu are combined, the sum of these impurities in % by weight is no more than 0.0030, preferably no more than 0.0021, and particularly preferably no more than 0.0009.
6. The magnesium alloy according to claim 2, characterized in that the alloy has a fine-grained micro structure having a grain size of < 7.5 μιη, preferably <5 μιη, and still more preferably < 2.5 μιη, without considerable electrochemical potential differences between the individual matrix phases.
7. The magnesium alloy according to claim 3, characterized in that the alloy matrix contains only such precipitations which have no potential differences, or potential differences as small as possible, as compared to the matrix, or which are less noble than the matrix.
8. The magnesium alloy according to claim 1, characterized in that the precipitations have a size of 1 μιη, and preferably < 0.2 μιη, and are dispersely distributed at the grain boundaries or in the grain interior.
9. The magnesium alloy according to claim 1, characterized in that it has a tensile strength of >275 MPa, and preferably >300 MPa, a yield point of >200 MPa, and preferably≥225 MPa, and a yield ratio of <0.8, and preferably <0.75, wherein the difference between the tensile strength and yield point is≥50 MPa, and preferably ≥100 MPa, and the mechanical asymmetry is <1.25.
10. A method for producing a magnesium alloy having improved mechanical and electrochemical properties, comprising the following steps:
a) generating high-purity magnesium by way of vacuum distillation;
b) generating a billet of the alloy by synthesis of the magnesium according to step a) with high-purity Zn and Al in a composition of 1.5 to 7.0% by weight Zn, 0.5 to 3.5% by weight Al, the remainder being magnesium containing impurities, which promote electrochemical potential differences and/or the formation of precipitations and/or intermetallic phases, in a total amount of no more than 0.0063% by weight of Fe, Si, Mn, Co, Ni, Cu, Zr, Y and Sc or rare earths having the ordinal numbers 21, 57 to 71 and 89 to 103, Be, Cd, In, Sn and/or Pb as well as P, wherein the alloy content of Zn in % by weight is greater than or equal to the alloy content of Al in % by weight;
c) homogenizing the alloy by annealing at a temperature between 250°C and 350°C with a holding period of 1 to 60 hours and cooling by exposure to air and in a water bath;
d) at least single forming of the homogenized alloy in the temperature range between 250°C and 350°C, prefereably 270°C and 350°C; and
e) optionally heat treating the formed alloy in the temperature range between 200°C and 350°C with a holding period of 5 minutes to 6 hours.
11. The method according to claim 10, characterized in that the content of Zn is preferably 1.5 to 5.5% by weight, and more particularly 3.0 to 5.5% by weight, and the content of Al is preferably at least 0.2 to 2.0% by weight, and more particularly 1.0 to 2.0% by weight, wherein the microstructure of the alloy is a mixed crystal made of Zn and Al, which are present completely in solution form, without precipitations.
12. The method according to claim 10, characterized in that the content of Zn is preferably 3.0 to 7.0% by weight, and more particularly 4.0 to 6.0%> by weight, and the content of Al is preferably 0.5 to 3.5% by weight, and more particularly 1.5 to 2.5% by weight, wherein the matrix of the alloy contains only precipitations in the form of Mg3Zn3Al2 and MgZn.
13. The method according to claim 10 or claim 11, characterized in that the alloying elements are not contained in an amount above the solubility limit, and a formation of precipitations in the alloy matrix is suppressed by the forming and heat treatment processes below the solubility limit, the precipitations forming cathodes which expedite corrosion as compared to the alloy matrix.
14. The method according to claim 10 or claim 12, characterized in that the alloying elements are contained in an amount slightly above the solubility limit, and the precipitations from the forming and heat treatment processes at temperatures below the solubility limit, preferably in the range of 200°C to 350°C, are used to adjust the strength.
15. The method according to claim 13 or claim 14, characterized in that the precipitations have a size of 1 μιη, and preferably < 0.2 μιη, and are dispersely distributed at the grain boundaries or in the grain interior.
16. The method according to claim 10, characterized in that the individual impurities in the total sum of impurities amount to the following in % by weight: Fe <0.0005; Si <0.0005; Mn <0.0005; Co <0.0005; Ni <0.0005; Cu <0.0005; Zr <0.0003; Y <0.0003; Sc or rare earths having the ordinal numbers 21, 57 to 71 and 89 to 103 <0.0010; Be, Cd, In, Sn and/or Pb each with <0.0003; and P <0.0002.
17. The method according to claim 10, characterized in that when the impurity elements Fe, Si, Mn, Co, Ni, and Cu are combined, the sum of these impurities in % by weight is no more than 0.0040, preferably no more than 0.020, and particularly preferably no more than 0.0010.
18. The method according to claim 10, characterized in that the forming process is an extrusion, equal channel angular extrusion (EACE) and/or multiple forging process.
19. Use of a magnesium alloy according to any one of the claims 1 to 9 for producing a biodegradable implant.
20. Use of a magnesium alloy according to claim 19, characterized in that the implant is elected from the group of endovascular implants such as stents, implants for fastening and temporarily fixing tissue implants and tissue transplantations, orthopedic and dental implants, and neuroimplants.
21. Use of a magnesium alloy produced by the method according to any one of the claims 10 to 18 for producing a biodegradable implant.
22. Use of a magnesium alloy according to claim 21, characterized in that the implant is elected from the group of endovascular implants such as stents, implants for fastening and temporarily fixing tissue implants and tissue transplantations, orthopedic and dental implants, and neuroimplants.
PCT/EP2013/062876 2012-06-26 2013-06-20 Magnesium alloy, method for the production thereof and use thereof WO2014001191A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CA2869458A CA2869458C (en) 2012-06-26 2013-06-20 Magnesium alloy, method for the production thereof and use thereof
KR1020147033397A KR102246885B1 (en) 2012-06-26 2013-06-20 Magnesium alloy, method for the production thereof and use thereof
JP2015518992A JP6786214B2 (en) 2012-06-26 2013-06-20 Magnesium alloy, its manufacturing method and its use
EP13729770.1A EP2864514B1 (en) 2012-06-26 2013-06-20 Implant made from a magnesium alloy, method for the production thereof and use thereof
CN201380022714.6A CN104284993B (en) 2012-06-26 2013-06-20 Magnesium alloy, its production method and application thereof
RU2015102168A RU2647951C2 (en) 2012-06-26 2013-06-20 Magnesium alloy, method for production thereof and use thereof
AU2013283577A AU2013283577A1 (en) 2012-06-26 2013-06-20 Magnesium alloy, method for the production thereof and use thereof
SG11201406024QA SG11201406024QA (en) 2012-06-26 2013-06-20 Magnesium alloy, method for the production thereof and use thereof
ES13729770T ES2796371T3 (en) 2012-06-26 2013-06-20 Magnesium alloy, method for its production and use of it
US14/395,954 US10895000B2 (en) 2012-06-26 2013-06-20 Magnesium alloy, method for the production thereof and use thereof
BR112014032618-5A BR112014032618B1 (en) 2012-06-26 2013-06-20 MAGNESIUM ALLOY, METHOD FOR ITS PRODUCTION AND HOW TO USE THE ALLOY
HK15101370.1A HK1200881A1 (en) 2012-06-26 2015-02-06 Magnesium alloy, method for the production thereof and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261664229P 2012-06-26 2012-06-26
US61/664,229 2012-06-26

Publications (1)

Publication Number Publication Date
WO2014001191A1 true WO2014001191A1 (en) 2014-01-03

Family

ID=48652113

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/062876 WO2014001191A1 (en) 2012-06-26 2013-06-20 Magnesium alloy, method for the production thereof and use thereof

Country Status (12)

Country Link
US (1) US10895000B2 (en)
EP (1) EP2864514B1 (en)
JP (2) JP6786214B2 (en)
KR (1) KR102246885B1 (en)
CN (1) CN104284993B (en)
AU (1) AU2013283577A1 (en)
CA (1) CA2869458C (en)
ES (1) ES2796371T3 (en)
HK (1) HK1200881A1 (en)
RU (2) RU2017138378A (en)
SG (1) SG11201406024QA (en)
WO (1) WO2014001191A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104233123A (en) * 2014-08-26 2014-12-24 盐城市鑫洋电热材料有限公司 Mg-Al-Cd-Zn intensified magnesium-based alloy and preparation method thereof
CN104233029A (en) * 2014-09-24 2014-12-24 中南大学 High-strength degradable magnesium alloy and preparation method thereof
EP2992925A1 (en) 2014-09-04 2016-03-09 BIOTRONIK SE & Co. KG Intravascular electrode lead and intravascular stimulation device including the same
CN107217185A (en) * 2017-06-03 2017-09-29 郑州汉东科技有限公司 A kind of degradable medical implant
JP2018517662A (en) * 2015-06-15 2018-07-05 ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. Apparatus and method for therapeutic heat treatment
WO2022152587A1 (en) 2021-01-15 2022-07-21 Biotronik Se & Co. Kg Medical implant, particularly in form of an implantable intracardiac pacemaker, comprising a rotatable anchoring device to allow extraction of the encapsulated medical implant
WO2022152470A1 (en) 2021-01-15 2022-07-21 Biotronik Se & Co. Kg A medical implant anchoring element with improved characteristics for implantation and retention
WO2022152586A1 (en) 2021-01-15 2022-07-21 Biotronik Se & Co. Kg Implantable medical device
WO2022152585A1 (en) 2021-01-15 2022-07-21 Biotronik Se & Co. Kg Implantable medical device

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2864513B1 (en) 2012-06-26 2022-02-23 Biotronik AG Biodegradable implant made from magnesium-aluminum-zinc alloy and method for the production thereof
EP2864516B1 (en) 2012-06-26 2020-05-06 Biotronik AG Implant made from magnesium-zinc-calcium alloy, and method for production thereof
SG11201406026TA (en) 2012-06-26 2014-10-30 Biotronik Ag Magnesium-zinc-calcium alloy, method for production thereof, and use thereof
SG11201406024QA (en) 2012-06-26 2014-10-30 Biotronik Ag Magnesium alloy, method for the production thereof and use thereof
CN105886804B (en) * 2016-05-16 2017-10-17 扬州大学 A kind of preparation method of high-performance Mg-Zn based alloy
RU2615930C1 (en) * 2016-06-16 2017-04-11 Юлия Алексеевна Щепочкина Magnesium solder
CN107587020B (en) * 2016-07-08 2019-10-22 中国科学院金属研究所 A kind of high thermal conductivity magnesium alloy and preparation method thereof
WO2018083998A1 (en) * 2016-11-02 2018-05-11 国立大学法人 熊本大学 Bioabsorbable medical device and method for producing same
CN108070762A (en) * 2016-11-17 2018-05-25 比亚迪股份有限公司 A kind of wrought magnesium alloy and preparation method thereof
CN106868369A (en) * 2017-03-17 2017-06-20 扬州大学 A kind of preparation method of single-phase supersaturated solid solution magnesium-zinc alloy
CN107142431B (en) * 2017-06-01 2018-09-11 哈尔滨工业大学 A kind of method that AZ80A magnesium alloys forging stock squeezes multiway forging combination process raising intensity
EP3415651A1 (en) * 2017-06-14 2018-12-19 Heraeus Deutschland GmbH & Co. KG A method for manufacturing a passivated product
CN108502007A (en) * 2018-03-12 2018-09-07 张纪校 A kind of magnesium alloy stroller
USD903393S1 (en) 2019-04-03 2020-12-01 Enfant Terrible Design AB Sun canopy
CN109913723A (en) * 2019-04-08 2019-06-21 常熟理工学院 The gradient porous magnesium alloy materials and die casting equipment of bone defect healing
US11697869B2 (en) 2020-01-22 2023-07-11 Heraeus Deutschland GmbH & Co. KG Method for manufacturing a biocompatible wire
CN114045409B (en) * 2021-11-16 2022-11-15 湖南华翔医疗科技有限公司 Orthopedic repair implant and preparation method thereof
CN115505858B (en) * 2022-09-29 2023-05-09 上海交通大学 Heat treatment method for large complex magnesium-rare earth alloy component

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1959025A1 (en) * 2005-11-16 2008-08-20 National Institute for Materials Science Magnesium-based biodegradable metal material
CN101308105B (en) * 2007-05-16 2010-08-11 北京有色金属研究总院 Rare-earth magnesium alloy solidification process thermal analysis device
EP2295613A1 (en) * 2008-06-03 2011-03-16 National Institute for Materials Science Mg-BASE ALLOY
WO2011114931A1 (en) * 2010-03-17 2011-09-22 独立行政法人物質・材料研究機構 Magnesium alloy
US20110315282A1 (en) * 2009-01-19 2011-12-29 Hidetoshi Somekawa Mg-BASE ALLOY

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US102A (en) * 1861-08-13 Whole
US692A (en) * 1838-04-14 Improvement in machines for mowing and cutting grass and grain
US3320055A (en) 1964-08-19 1967-05-16 Dow Chemical Co Magnesium-base alloy
CH672417A5 (en) 1987-06-17 1989-11-30 Sulzer Ag
JPH0247238A (en) 1988-08-08 1990-02-16 Nippon Telegr & Teleph Corp <Ntt> High-damping alloy and its production
US5055254A (en) 1989-10-05 1991-10-08 Timminco Limited Magnesium-aluminum-zinc alloy
JP3204572B2 (en) 1993-06-30 2001-09-04 株式会社豊田中央研究所 Heat resistant magnesium alloy
US5582630A (en) * 1995-02-21 1996-12-10 Sony Corporation Ultra high purity magnesium vacuum distillation purification method
KR970070222A (en) 1996-04-25 1997-11-07 박병재 Magnesium alloy for high pressure casting
RU2098506C1 (en) 1996-06-06 1997-12-10 Ольга Васильевна Деткова Magnesium-base alloy
KR19980702359A (en) * 1997-08-20 1998-07-15 터그럴 야사르 Ultra high purity magnesium and vacuum distillation purification method and apparatus
AU2002950563A0 (en) 2002-08-02 2002-09-12 Commonwealth Scientific And Industrial Research Organisation Age-Hardenable, Zinc-Containing Magnesium Alloys
WO2005108634A1 (en) 2004-05-10 2005-11-17 Norsk Hydro Technology B.V. Magnesium alloy having improved elevated temperature performance
CN1743486A (en) 2004-08-31 2006-03-08 唐智荣 Alloy as magnesium element as matrix and its use as bone-fracture internal fixer
CN1792383A (en) 2005-12-22 2006-06-28 上海交通大学 Bio-absorbable Mg-Zn-Ca three-elements magnesium alloy material
CN100368028C (en) 2005-12-22 2008-02-13 上海交通大学 Bio-absorbable Mg-Zn two-elements magnesium alloy material
DE102006015457A1 (en) 2006-03-31 2007-10-04 Biotronik Vi Patent Ag Magnesium alloy and related manufacturing process
JP5429702B2 (en) 2006-08-03 2014-02-26 独立行政法人物質・材料研究機構 Magnesium alloy and manufacturing method thereof
WO2008035948A1 (en) 2006-09-22 2008-03-27 U & I Corporation Implants comprising biodegradable metals and method for manufacturing the same
DE102006060501A1 (en) 2006-12-19 2008-06-26 Biotronik Vi Patent Ag Forming corrosion-inhibiting anodized coating on bio-corrodible magnesium alloy implant, treats implant in aqueous or alcoholic solution containing specified ion concentration
AU2007202131A1 (en) 2007-05-14 2008-12-04 Joka Buha Method of heat treating magnesium alloys
GB0721693D0 (en) 2007-11-05 2007-12-12 Univ Bristol Antenna for investigating structure of human or animal
DE102008006455A1 (en) 2008-01-29 2009-07-30 Biotronik Vi Patent Ag Implant comprising a body made of a biocorrodible alloy and a corrosion-inhibiting coating
KR101289122B1 (en) 2008-03-18 2013-07-23 한국보건산업진흥원 COMPLEX IMPLANTS INFILTERATED WITH BIODEGRADABLE Mg(ALLOYS) INSIDE POROUS STRUCTURAL MATERIALS AND METHOD FOR MANUFACTURING THE SAME
JP5467294B2 (en) 2008-06-05 2014-04-09 独立行政法人産業技術総合研究所 Easy-formable magnesium alloy sheet and method for producing the same
JP2011524465A (en) 2008-06-06 2011-09-01 ジンテス ゲゼルシャフト ミット ベシュレンクテル ハフツング Absorbable magnesium alloy
CN101629260A (en) 2008-07-18 2010-01-20 中国科学院金属研究所 Medical absorbable Mg-Zn-Mn-Ca magnesium alloy
CN102098987B (en) * 2008-09-29 2014-02-19 泰尔茂株式会社 Stent for placement in living body, and stent delivery system
JP5336204B2 (en) * 2009-01-13 2013-11-06 株式会社神戸製鋼所 Magnesium alloy with excellent balance between anisotropy and yield strength
AU2010239873A1 (en) 2009-04-22 2011-11-24 U&I Corporation Biodegradable implant and method for manufacturing same
CN101658691B (en) 2009-07-31 2013-03-13 哈尔滨工业大学 Method for plastically manufacturing high-purity magnesium alloy absorbable stent
DK2493523T3 (en) * 2009-10-30 2014-09-01 Acrostak Corp Bvi Tortola Biodegradable implantable medical devices designed from super pure magnesium based material
CN102639158A (en) 2009-12-07 2012-08-15 友和安股份公司 Implant
WO2011071304A2 (en) 2009-12-07 2011-06-16 유앤아이 주식회사 Magnesium alloy
JP5939372B2 (en) * 2010-03-30 2016-06-22 住友電気工業株式会社 Coil material and manufacturing method thereof
EP2384725B1 (en) 2010-05-06 2018-07-04 Biotronik AG Biocorrodable implant in which corrosion may be triggered or accelerated after implantation by means of an external stimulus
RU2437949C1 (en) 2010-06-23 2011-12-27 Учреждение Российской академии наук Институт металлургии и материаловедения им. А.А. Байкова РАН Cast composite material on base of magnesium alloy and procedure for its manufacture
US9561308B2 (en) 2010-06-25 2017-02-07 Fort Wayne Metal Research Products Corporation Biodegradable composite wire for medical devices
AT510087B1 (en) 2010-07-06 2012-05-15 Ait Austrian Institute Of Technology Gmbh MAGNESIUM ALLOY
CN102312144A (en) 2010-07-07 2012-01-11 乐普(北京)医疗器械股份有限公司 Ultrafine-grain medical magnesium alloy and preparation method thereof
DE102010027532B8 (en) 2010-07-16 2014-09-18 Aap Biomaterials Gmbh Process for PEO coating
CN101899600B (en) 2010-08-13 2012-04-25 上海交通大学 Osteopathic magnesium alloy interstitial implant material and preparation method thereof
JP5720926B2 (en) 2010-10-12 2015-05-20 住友電気工業株式会社 Magnesium alloy wire, bolt, nut and washer
CN101948957B (en) * 2010-10-14 2012-07-04 宁波翔博机械有限公司 Vacuum distillation method for magnesium alloy
EP2629810A1 (en) 2010-10-18 2013-08-28 Boston Scientific Scimed, Inc. Medical implant including a magnesium-based tie layer
DE102011011344B4 (en) 2011-02-16 2014-12-11 Audi Ag Circuit arrangement for an electric seat heating
WO2013069638A1 (en) 2011-11-07 2013-05-16 トヨタ自動車株式会社 HIGH STRENGTH Mg ALLOY AND METHOD FOR PRODUCING SAME
SG11201404182XA (en) 2012-01-19 2014-09-26 Eth Zuerich Process and apparatus for vacuum distillation of high-purity magnesium
SG11201406024QA (en) 2012-06-26 2014-10-30 Biotronik Ag Magnesium alloy, method for the production thereof and use thereof
EP2864513B1 (en) * 2012-06-26 2022-02-23 Biotronik AG Biodegradable implant made from magnesium-aluminum-zinc alloy and method for the production thereof
EP2864516B1 (en) 2012-06-26 2020-05-06 Biotronik AG Implant made from magnesium-zinc-calcium alloy, and method for production thereof
SG11201406026TA (en) 2012-06-26 2014-10-30 Biotronik Ag Magnesium-zinc-calcium alloy, method for production thereof, and use thereof
US9469889B2 (en) 2012-08-31 2016-10-18 DePuy Synthes Products, Inc. Ultrapure magnesium alloy with adjustable degradation rate
BR112015022632B1 (en) 2013-03-14 2020-01-07 DePuy Synthes Products, Inc. MAGNESIUM ALLOY COMPOSITION, IMPLANT, AND COMPOSITION PRODUCTION METHOD
US9593397B2 (en) 2013-03-14 2017-03-14 DePuy Synthes Products, Inc. Magnesium alloy with adjustable degradation rate
US9398945B2 (en) 2013-09-19 2016-07-26 Cook Medical Technologies Llc Vascular implant retrieval assembly and method

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1959025A1 (en) * 2005-11-16 2008-08-20 National Institute for Materials Science Magnesium-based biodegradable metal material
CN101308105B (en) * 2007-05-16 2010-08-11 北京有色金属研究总院 Rare-earth magnesium alloy solidification process thermal analysis device
EP2295613A1 (en) * 2008-06-03 2011-03-16 National Institute for Materials Science Mg-BASE ALLOY
US20110315282A1 (en) * 2009-01-19 2011-12-29 Hidetoshi Somekawa Mg-BASE ALLOY
WO2011114931A1 (en) * 2010-03-17 2011-09-22 独立行政法人物質・材料研究機構 Magnesium alloy

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHEN JI-HUA ET AL: "Microstructural stability and mechanical properties of Mg-Zn-Al alloys", HUNAN-DAXUE-XUEBAO / ZIRAN-KEXUE-BAN = JOURNAL OF HUNAN UNIVERSITY / HUNAN DAXUE ZHUBAN,, vol. 34, no. 1, 1 January 2007 (2007-01-01), pages 47 - 51, XP009172892, ISSN: 1674-2974 *
HORST E. FRIEDRICH, BARRY L. MORDIKE: "Magnesium Technology", 1 January 2006, SPRINGER, Berlin Heidelberg New York, ISBN: 3-540-20599-3, XP002713981 *
KIM YE-LIM ET AL: "Effect of Al addition on the precipitation behavior of a binary Mg-Zn alloy", HAN'GUG JAERYO HAGHOEJI - KOREAN JOURNAL OF MATERIALS RESEARCH, HAN'GUG JAERYO HAGHOE, SEOUL, KR, vol. 22, no. 3, 1 January 2012 (2012-01-01), pages 111 - 117, XP009173103, ISSN: 1225-0562 *
LIU QIANG ET AL: "Influences of Al on microstructures and properties of Mg-6Zn alloys", KUANGYE-GONGCHENG = MINING AND METALLURGICAL ENGINEERING,, vol. 25, no. 5, 1 October 2005 (2005-10-01), pages 74 - 76, XP009172891, ISSN: 0253-6099 *
ZOU ET AL: "Effects of microstructure on creep behavior of Mg-5%Zn-2%Al(-2%Y) alloy", TRANSACTIONS OF NONFERROUS METALS SOCIETY OF CHINA, NONFERROUS METALS SOCIETY OF CHINA, CN, vol. 18, no. 3, 1 June 2008 (2008-06-01), pages 580 - 587, XP022936020, ISSN: 1003-6326, [retrieved on 20080601], DOI: 10.1016/S1003-6326(08)60101-6 *
ZOU H ET AL: "EFFECTS OF ND ON THE MICROSTRUCTURE AND MECHANICAL PROPERTY OF ZA52 ALLOY", MATERIALS SCIENCE FORUM, TRANS TECH PUBLICATIONS LTD- SWITZERLAND, CH, vol. 488/489, 1 June 2005 (2005-06-01), pages 161 - 164, XP008065140, ISSN: 0255-5476 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104233123A (en) * 2014-08-26 2014-12-24 盐城市鑫洋电热材料有限公司 Mg-Al-Cd-Zn intensified magnesium-based alloy and preparation method thereof
EP2992925A1 (en) 2014-09-04 2016-03-09 BIOTRONIK SE & Co. KG Intravascular electrode lead and intravascular stimulation device including the same
US9821154B2 (en) 2014-09-04 2017-11-21 Biotronik Se & Co. Kg Intravascular electrode lead and intravascular stimulation device including the same
CN104233029A (en) * 2014-09-24 2014-12-24 中南大学 High-strength degradable magnesium alloy and preparation method thereof
JP2018517662A (en) * 2015-06-15 2018-07-05 ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. Apparatus and method for therapeutic heat treatment
US11147874B2 (en) 2015-06-15 2021-10-19 Boston Scientific Scimed, Inc. Devices and methods for therapeutic heat treatment
CN107217185A (en) * 2017-06-03 2017-09-29 郑州汉东科技有限公司 A kind of degradable medical implant
CN107217185B (en) * 2017-06-03 2021-02-12 西南医科大学 Degradable medical implant
WO2022152587A1 (en) 2021-01-15 2022-07-21 Biotronik Se & Co. Kg Medical implant, particularly in form of an implantable intracardiac pacemaker, comprising a rotatable anchoring device to allow extraction of the encapsulated medical implant
WO2022152470A1 (en) 2021-01-15 2022-07-21 Biotronik Se & Co. Kg A medical implant anchoring element with improved characteristics for implantation and retention
WO2022152586A1 (en) 2021-01-15 2022-07-21 Biotronik Se & Co. Kg Implantable medical device
WO2022152585A1 (en) 2021-01-15 2022-07-21 Biotronik Se & Co. Kg Implantable medical device

Also Published As

Publication number Publication date
JP2019148012A (en) 2019-09-05
CN104284993B (en) 2017-06-23
ES2796371T3 (en) 2020-11-26
EP2864514A1 (en) 2015-04-29
RU2017138378A (en) 2019-02-11
US20150119995A1 (en) 2015-04-30
SG11201406024QA (en) 2014-10-30
US10895000B2 (en) 2021-01-19
HK1200881A1 (en) 2015-08-14
JP6786214B2 (en) 2020-11-18
EP2864514B1 (en) 2020-04-29
BR112014032618A2 (en) 2017-06-27
KR20150023311A (en) 2015-03-05
KR102246885B1 (en) 2021-05-03
CN104284993A (en) 2015-01-14
CA2869458A1 (en) 2014-01-03
JP2015528052A (en) 2015-09-24
CA2869458C (en) 2021-04-06
RU2015102168A (en) 2016-08-20
RU2647951C2 (en) 2018-03-21
AU2013283577A1 (en) 2014-10-09

Similar Documents

Publication Publication Date Title
US10995398B2 (en) Corrosion resistant stent
EP2864514B1 (en) Implant made from a magnesium alloy, method for the production thereof and use thereof
US10358709B2 (en) Magnesium-zinc-calcium alloy, method for production thereof, and use thereof
US11499214B2 (en) Magnesium-zinc-calcium alloy and method for producing implants containing the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13729770

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2869458

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2013283577

Country of ref document: AU

Date of ref document: 20130620

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14395954

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2015518992

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20147033397

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2013729770

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2015102168

Country of ref document: RU

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014032618

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014032618

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20141226